Il trattamento dell'iperparatiroidismo secondario con gli analoghi della vitamina D

Abstract

Get full access to this article

View all access options for this article.

References

Slatopolsky

A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852–60.

Martin

K.J.

19-Nor-1,25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427–32.

Martin

K.J.

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized trial. Am J Kidney Dis 2001; 38(suppl 5): S57–63.

Mitsopoulos

Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 2006; 48: 114–21.

Llach

, Yudd

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38(suppl 5): S45–50.

Sprague

S.M.

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003 63: 1483–90.

Drueke

T.B.

, McCarron

D.A.

Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. New Engl J Med 2003; 349: 496–9.

Gallieni

Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42: 1191–8.

Teng

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446–56.

10.

Teng

Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25.

11.

Brown

Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transpl 2002; 17(suppl 10): S10–9.

12.

Sjoden

1 -Hydroxyvitamin D2 is less toxic than 1 -hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432–6.

13.

Maung

H.M.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1 -hydroxyvitamin D 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532–43.

14.

Tentori

Survival among hemodialysis patients receiving intravenous doxercalciferol and paricalcitol versus calcitriol. J Am Soc Nephrol 2005; 16: 279A

15.

Tentori

Decreased odds of hospitalization among hemodialysis patients receiving doxercalciferol and paricalcitol versus calcitriolo. J Am Soc Nephrol 2005; 16: 279A

16.

Brown

A.J.

The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728–32.

17.

Kubrusly

Effect of 22-oxacalcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993; 44: 551–6.

18.

Akizawa

Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004; 8: 480–91.

19.

Hayashi

Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 2004; 19: 2067–73.

20.

Nishizawa

Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on hemodialysis: preliminary report. Contrib Nephrol 1991; 90: 196–203.

21.

Fan

SLS

Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol. Nephrol Dial Transplant 2000; 15: 1943–9.

22.

Hruby

Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 1781–6.

23.

Lippuner

1,25-(OH)2-16ene-23yne-D 3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect. Horm Res 2004; 61: 7–16.

24.

Brown

A.J.

Isolation and identification of 1 -hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion. J Cell Biochem 2005; 96: 569–78.

25.

Plum

L.A.

Biologically active noncalcemic analogs of 1,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 2004; 101: 6900–04.

26.

Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006; 116: 892–904.

27.

Brown

A.J.

, Slatopolsky

Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nature Clin Practice Endocrinol Metabol 2007; 3: 134–44.

28.

Segersten

25-hydroxyvitamin D3-1 -hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 2002; 87: 2967–72.

29.

Ritter

C.S.

25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by cultured bovine parathyroid cells: potential role for intracrine 1,25-dihydroxyvitamin D3. Kidney Int 2006; 70: 654–9.

30.

Gallieni

Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746–53.